UK ENcorafenib and BInimetinib Real-world Study in Melanoma (UK-EnBiRiM)
UK ENcorafenib and BInimetinib Real-world Study in Melanoma (UK-EnBiRiM)
UK ENcorafenib and BInimetinib Real-world Study in Melanoma (UK-EnBiRiM)
Status
Status :
Active not recruiting
Type of study
Min. Age
18
Years old
Max. Age
-
Gender
All
Therapeutic area :
Oncology
Disease :
Metastatic melanoma
Study medication :
Encorafenib (BRAFTOVI®) - Binimetinib (MEKTOVI®)
Start Date :
July 31, 2025
End date :
July 31, 2028
Study ID :
5126-10-2024
CT.gov Number :
NCT07022457
Sponsor(s) or Co-Sponsor(s) :
Pierre Fabre Ltd (United Kingdom)
This study is sponsored by Pierre Fabre Ltd (United Kingdom). Full details of the study can be found at: Study details | NCT07022457 | UK study of encorafenib and binimetinib in melanoma | ClinicalTrials.gov
Send by email